FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2728077452> ?p ?o ?g. }

• W2728077452 endingPage "583" @default.
• W2728077452 startingPage "573" @default.
• W2728077452 abstract "The prospective phase 3 PlanB trial used the Oncotype DX® Recurrence Score® (RS) to define a genomically low-risk subset of clinically high-risk pN0-1 early breast cancer (EBC) patients for treatment with adjuvant endocrine therapy (ET) alone. Here, we report five-year data evaluating the prognostic value of RS, Ki-67, and other traditional clinicopathological parameters.A central tumour bank was prospectively established within PlanB. Following an early amendment, hormone receptor (HR)+ , pN0-1 RS ≤ 11 patients were recommended to omit chemotherapy. Patients with RS ≥ 12, pN2-3, or HR-negative/HER2-negative disease were randomised to anthracycline-containing or anthracycline-free chemotherapy. Primary endpoint: disease-free survival (DFS). PlanB Clinicaltrials.gov identifier: NCT01049425.From 2009 to 2011, PlanB enrolled 3198 patients (central tumour bank, n = 3073) with the median age of 56 years, 41.1% pN+, and 32.5% grade 3 EBC. Chemotherapy was omitted in 348/404 (86.1%) eligible RS ≤ 11 patients. After 55 months of median follow-up, five-year DFS in ET-treated RS ≤ 11 patients was 94% (in both pN0 and pN1) versus 94% (RS 12-25) and 84% (RS > 25) in chemotherapy-treated patients (p < 0.001); five-year overall survival (OS) was 99 versus 97% and 93%, respectively (p < 0.001). Nodal status, central/local grade, tumour size, continuous Ki-67, progesterone receptor (PR), IHC4, and RS were univariate prognostic factors for DFS. In a multivariate analysis including all univariate prognostic markers, only pN2-3, central and local grade 3, tumour size >2 cm, and RS, but not IHC4 or Ki-67 were independent adverse factors. If RS was excluded, IHC4 or both Ki-67 and PR entered the model. The impact of RS was particularly pronounced in patients with intermediate Ki-67 (>10%, <40%) tumours.The excellent five-year outcomes in clinically high-risk, genomically low-risk (RS ≤ 11) pN0-1 patients without adjuvant chemotherapy support using RS with standardised pathology for treatment decisions in HR+ HER2-negative EBC. Ki-67 has the potential to support patient selection for genomic testing." @default.
• W2728077452 created "2017-07-14" @default.
• W2728077452 creator A5002071285 @default.
• W2728077452 creator A5012681752 @default.
• W2728077452 creator A5014363979 @default.
• W2728077452 creator A5016623639 @default.
• W2728077452 creator A5022444628 @default.
• W2728077452 creator A5025009422 @default.
• W2728077452 creator A5027231412 @default.
• W2728077452 creator A5027450608 @default.
• W2728077452 creator A5031666050 @default.
• W2728077452 creator A5038841214 @default.
• W2728077452 creator A5040331693 @default.
• W2728077452 creator A5042364191 @default.
• W2728077452 creator A5044665296 @default.
• W2728077452 creator A5045520566 @default.
• W2728077452 creator A5048307202 @default.
• W2728077452 creator A5048859997 @default.
• W2728077452 creator A5049792647 @default.
• W2728077452 creator A5050978422 @default.
• W2728077452 creator A5052512508 @default.
• W2728077452 creator A5054650117 @default.
• W2728077452 creator A5068847492 @default.
• W2728077452 date "2017-06-29" @default.
• W2728077452 modified "2023-10-18" @default.
• W2728077452 title "Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial" @default.
• W2728077452 cites W1961026612 @default.
• W2728077452 cites W2044702943 @default.
• W2728077452 cites W2074820139 @default.
• W2728077452 cites W2096910745 @default.
• W2728077452 cites W2097255042 @default.
• W2728077452 cites W2105882193 @default.
• W2728077452 cites W2112894406 @default.
• W2728077452 cites W2113344831 @default.
• W2728077452 cites W2118632896 @default.
• W2728077452 cites W2119565091 @default.
• W2728077452 cites W2125702566 @default.
• W2728077452 cites W2127057139 @default.
• W2728077452 cites W2130639106 @default.
• W2728077452 cites W2144535237 @default.
• W2728077452 cites W2150134401 @default.
• W2728077452 cites W2152121590 @default.
• W2728077452 cites W2157706516 @default.
• W2728077452 cites W2160377567 @default.
• W2728077452 cites W2160450758 @default.
• W2728077452 cites W2173858545 @default.
• W2728077452 cites W2190954851 @default.
• W2728077452 cites W2259802687 @default.
• W2728077452 cites W2289933199 @default.
• W2728077452 cites W2303905424 @default.
• W2728077452 cites W2319824849 @default.
• W2728077452 cites W2400686733 @default.
• W2728077452 cites W2407306171 @default.
• W2728077452 cites W2410853227 @default.
• W2728077452 cites W2509844702 @default.
• W2728077452 cites W2515549918 @default.
• W2728077452 cites W2517421365 @default.
• W2728077452 cites W2591752566 @default.
• W2728077452 cites W2592904882 @default.
• W2728077452 doi "https://doi.org/10.1007/s10549-017-4358-6" @default.
• W2728077452 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6491403" @default.
• W2728077452 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30632020" @default.
• W2728077452 hasPublicationYear "2017" @default.
• W2728077452 type Work @default.
• W2728077452 sameAs 2728077452 @default.
• W2728077452 citedByCount "134" @default.
• W2728077452 countsByYear W27280774522017 @default.
• W2728077452 countsByYear W27280774522018 @default.
• W2728077452 countsByYear W27280774522019 @default.
• W2728077452 countsByYear W27280774522020 @default.
• W2728077452 countsByYear W27280774522021 @default.
• W2728077452 countsByYear W27280774522022 @default.
• W2728077452 countsByYear W27280774522023 @default.
• W2728077452 crossrefType "journal-article" @default.
• W2728077452 hasAuthorship W2728077452A5002071285 @default.
• W2728077452 hasAuthorship W2728077452A5012681752 @default.
• W2728077452 hasAuthorship W2728077452A5014363979 @default.
• W2728077452 hasAuthorship W2728077452A5016623639 @default.
• W2728077452 hasAuthorship W2728077452A5022444628 @default.
• W2728077452 hasAuthorship W2728077452A5025009422 @default.
• W2728077452 hasAuthorship W2728077452A5027231412 @default.
• W2728077452 hasAuthorship W2728077452A5027450608 @default.
• W2728077452 hasAuthorship W2728077452A5031666050 @default.
• W2728077452 hasAuthorship W2728077452A5038841214 @default.
• W2728077452 hasAuthorship W2728077452A5040331693 @default.
• W2728077452 hasAuthorship W2728077452A5042364191 @default.
• W2728077452 hasAuthorship W2728077452A5044665296 @default.
• W2728077452 hasAuthorship W2728077452A5045520566 @default.
• W2728077452 hasAuthorship W2728077452A5048307202 @default.
• W2728077452 hasAuthorship W2728077452A5048859997 @default.
• W2728077452 hasAuthorship W2728077452A5049792647 @default.
• W2728077452 hasAuthorship W2728077452A5050978422 @default.
• W2728077452 hasAuthorship W2728077452A5052512508 @default.
• W2728077452 hasAuthorship W2728077452A5054650117 @default.
• W2728077452 hasAuthorship W2728077452A5068847492 @default.
• W2728077452 hasBestOaLocation W27280774521 @default.
• W2728077452 hasConcept C121608353 @default.
• W2728077452 hasConcept C126322002 @default.

• next